Related Researcher

Author's Photo

Ryu, Ja-Hyoung
Supramolecular NanoMaterials Lab (SUN)
Research Interests
  • Supramolecular assembly, synthetic peptide assembly, cancer drug delivery


Selective Tumor Treatment Targeting CAIX with Low Toxicity Range by Interrupting Lysosome

DC Field Value Language Kim, Dohyun ko Ryu, Ja-Hyoung ko 2020-12-24T00:38:25Z - 2020-12-23 ko 2020-06-07 ko
dc.identifier.citation 125th General Meeting of the Korean Chemical Society ko
dc.identifier.uri -
dc.description.abstract Lysosome, which degrades and recycles cellular waste, is a vital organelle to maintain cellular signaling and metabolism. Therefore, lysosome has been emerged as an efficient therapeutic target to treat cancer cell. To induce lysosomal disruption, researcher has been used self-assembly structure that interacts with organelle membrane. Carbonic anhydrase IX (CAIX), which is overexpressed cancer cell, has a key role to signal transduction of tumor including cell proliferation, metastasis, angiogenesis. CAIX targeting strategy has been developed to give selective cellular uptake by using Acetazolamide as a CAIX targeting moiety. Here, we developed Pep-AT containing acetazolamide, which is carbonic anhydrase IX targeting moiety, and triphenylphosphonium (TPP), which is organelle interacting moiety. As Pep-AT selectively binds CAIX of cancer cell, self-assembly structure of Pep-AT can be generated. Self-assembly structure can be encapsulated inside lysosome by CAIX-mediated endocytosis. Interaction between lysosomal membrane and self-assembly structure can induce lysosomal disruption, as followed by cellular apoptosis. ko
dc.publisher Korean Chemical Society ko
dc.title Selective Tumor Treatment Targeting CAIX with Low Toxicity Range by Interrupting Lysosome ko
dc.type CONFERENCE ko
dc.type.rims CONF ko
Appears in Collections:
CHM_Conference Papers

find_unist can give you direct access to the published full text of this article. (UNISTARs only)

Show simple item record


  • mendeley


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.